Biora Therapeutics, Inc.

Good day and thank you for standing by. Welcome to the Progenity Third Quarter 2021 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during that time, you will need to press star 1 on your telephone. If you require any further assistance, please press star 0. I would now like to turn the call over to our moderator today, Robert Yule. Managing Director with ICR Westwick Progenity's Investor Relations firm. Thank you. Please go ahead.

Thank you, operator. Good afternoon and welcome to Progenity's third quarter 2021 financial results conference call. Joining me on the call is Adi Mohanty, the new CEO of Progenity, and Eric Desparbis, Chief Financial Officer. Before I turn the call over to Mr. Mohanty, I would like to remind you that today's call will include forward-looking statements within the meaning of the federal securities laws, including but not limited to the types of statements identified as forward-looking in our quarterly report on Form 10-Q that we will file later today and our subsequent periodic reports filed with the SEC, which will all be available on our website in the Investors section. These forward-looking statements represent our views only as of the date of this call and involve substantial risks and uncertainties, including many that are beyond our control. Please note that the actual results could differ materially from those projected in any forward-looking statement. For a further description of the risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, as well as risks related to our business, please see our periodic reports filed with the SEC. A slide deck with some supplemental information is also now on the website, but it will not be directly referenced by the speakers on the call today. With that, I will now turn the call over to Adi Mohanty, the new CEO of Progenity.

Thank you, Robert. Hello, everyone. I'm happy to join our call today and really happy to have joined the company on such a pivotal time. While doing my diligence, I was absolutely impressed with the innovation, the science, and data behind the programs here at Progenity. These have the potential to have positive paradigm-changing impact on the diagnosis and treatment of serious diseases. The company has also made significant progress on its transformation. I'm looking forward to accelerating this process and creating clearer focus. Focus on doing the right thing for patients while also ensuring that we're doing the right thing for all our other stakeholders, our shareholders, our employees, our partners. In the coming days, we will accelerate our transformation, generate and capture value from our unique assets, have a clear focus on advancing our pipeline, and deliver for our current partners and explore further partnerships and collaboration while making efficient use of our resources. I look forward to coming back soon to talk about our progress. Now, I will turn the call over to Eric to cover our quarterly update.